Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DBH | P09172 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19615043 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL581175 | 0.95 | IDO1 (0.57) | TAAR1IDO1AGXTMIFALDH1A1 | |
| SCHEMBL3371633 | 0.79 | TAAR1 (0.74) | TAAR1IDO1AGXTMIFALDH1A1 | |
| SCHEMBL3300303 | 0.79 | TAAR1 (0.60) | TAAR1IDO1AGXTMIFALDH1A1 | |
| Bromide SCHEMBL31513714 | 0.78 | TAAR1 (0.65) | TAAR1IDO1AGXTMIFMAOB | |
| Bromide SCHEMBL16113497 | 0.78 | TAAR1 (0.54) | TAAR1IDO1AGXTMIFALDH1A1 | |
| SCHEMBL283775 | 0.77 | — | — | |
| SCHEMBL9971249 | 0.77 | — | — | |
| SCHEMBL5802285 | 0.75 | — | — | |
| SCHEMBL95076 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353856-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) | NORWEGIAN UNIV SCI & TECH NTNU (NO) | 2025-11-20 | — | — | US | disclosed |
| WO-2024079342-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2024-04-18 | — | — | WO | disclosed |
| EP-3458066-B1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3500570-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-109952301-B | 5-HT2C receptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20210214355-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10836764-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | US | disclosed |
| EP-2665724-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| CN-102770415-A | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS INC | 2012-11-07 | — | — | CN | disclosed |
| CN-102656168-A | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS INC | 2012-09-05 | — | — | CN | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097682-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| US-7989625-B2 | Thienopyridines | MERCK PATENT GMBH (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100048558-A1 | THIENOPYRIDINES | MERCK PATENT GESELLSCHAFT (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048558-A1 | THIENOPYRIDINES | HSP90AB2P, HSP90AB1, HSP90AA1 | SLC6A3 1368/4885SLC6A4 1033/4885TAAR1 1190/4885 |
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, TPH2 | SLC6A3 90/4885SLC6A4 79/4885TAAR1 76/4885 |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | SLC6A3 70/4885SLC6A4 26/4885TAAR1 110/4885 |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | SLC6A3 4222/4885SLC6A4 3493/4885TAAR1 1281/4885 |
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | PDE2A, PDE3A, PDE5A | SLC6A3 2038/4885SLC6A4 2570/4885TAAR1 1129/4885 |
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | PDE2A, PDE3A, PDE5A | SLC6A3 1966/4885SLC6A4 2528/4885TAAR1 1081/4885 |
| US-20210214355-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, TPH2 | SLC6A3 68/4885SLC6A4 75/4885TAAR1 54/4885 |
| US-20250353856-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) | CSF1R, CSF3R, IL1RN | SLC6A3 4611/4885SLC6A4 4791/4885TAAR1 437/4885 |
| US-10836764-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, TPH2 | SLC6A3 90/4885SLC6A4 79/4885TAAR1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.